Transcenta Holding (HKSE:06628) Other Financing: HK$-8.53 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06628 Transcenta Holding Ltd HKSE:06628
40 GF Score
Price HK$0.91
GF Value HK$0.29
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Transcenta Holding Other Financing?

Transcenta Holding HKSE:06628 +7.06% 40 Other Financing is HK$-8.53 Mil as of Dec. 2025. GuruFocus rates HKSE:06628 with a GF Score™ of 40/100 and a GF Value™ of HK$0.29 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Transcenta Holding's Other Financing for the six months ended in Dec. 2025 was HK$-4.50 Mil.

Transcenta Holding's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-8.53 Mil.

Transcenta Holding Other Financing Historical Data

* Premium members only.

The historical data trend for Transcenta Holding's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transcenta Holding Other Financing Chart

Transcenta Holding Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -52.79 -19.03 -17.09 -13.50 -8.57

Transcenta Holding Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.21 -7.37 -6.19 -4.02 -4.50
HKSE:06628
40GF Score
Transcenta Holding Ltd HKSE:06628
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transcenta Holding Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-8.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$-8.53 Mil mean?
Transcenta Holding (HKSE:06628) has a Other Financing of HK$-8.53 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Transcenta Holding and its competitors.
Is Transcenta Holding's Other Financing too high?
Transcenta Holding's current Other Financing is HK$-8.53 Mil. Overall, Transcenta Holding has a GF Score™ of 40/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Transcenta Holding's Other Financing compare to VRTX and REGN?
Transcenta Holding's Other Financing of HK$-8.53 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Transcenta Holding and its competitors. Transcenta Holding's current Other Financing is HK$-8.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transcenta Holding stock overvalued right now?
Based on GuruFocus' analysis, Transcenta Holding (HKSE:06628) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.91 — trading 213.8% above its estimated fair value. The current Other Financing is HK$-8.53 Mil. Transcenta Holding's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Transcenta Holding (HKSE:06628), the current Other Financing is HK$-8.53 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transcenta Holding (HKSE:06628) Overvalued in 2026?

Based on GuruFocus' analysis, Transcenta Holding stock appears to be overvalued. The current stock price of HK$0.91 is trading 213.8% above its estimated GF Value™ of HK$0.29. GuruFocus considers Transcenta Holding to be Significantly Overvalued.

Key valuation signals for HKSE:06628:

  • Other Financing: HK$-8.53 Mil
  • GF Value™: HK$0.29 vs. price of HK$0.91 (213.8% above fair value)
  • GF Score™: 40/100 with 6 warning signs

No single metric tells the full story. See the HKSE:06628 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transcenta Holding Business Description

Address B6-501, 218 Xinghu Street, Biobay, Suzhou, CHN, 215123
Transcenta Holding Ltd is a clinical-stage biopharmaceutical company with fully integrated capabilities across discovery, research, clinical development, and manufacturing, uniquely positioned to advance high-impact biologic innovations with commercial potential. The company's asset, Osemitamab (TST001), is a anti-Claudin18.2 monoclonal antibody currently advancing toward late-stage development. It is building a differentiated pipeline spanning oncology, osteoporosis, kidney disease, and autoimmune disorders. It operates in a single segment and geographically its operations are spread across Chinese mainland, United States of America, and Others with Chinese Mainland deriving the majority of revenue.
40GF Score

Get the complete analysis for HKSE:06628

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.91
Price
HK$0.29
GF Value